Market News & Trends
Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO
Daré to receive $1.8-million payment; eligible for additional potential milestone payments of up to $180 million and tiered double-digit royalties based on net sales…..
Silo Pharma’s Peptide Shows Positive Results Against Rheumatoid Arthritis
Silo Pharma, Inc. recently announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human…
Nemera Extends Manufacturing Capabilities in North America
With a newly acquired space in Vernon Hills, IL, Nemera opens a third location in the United States, in addition to the manufacturing facility in Buffalo Grove and Innovation center in Chicago….
eXmoor Completes Expansion Into Full-Service Cell & Gene Therapy CDMO Partner With Opening of GMP Facilities
eXmoor pharma recently launched its new Cell and Gene Therapy Centre GMP facility, to support the simultaneous production of multiple therapies for clinical trials. The…
Ashland Showcases New Bioresorbable Polymers Technology Platform, Pharmaceutical Products & Solutions
Ashland is showcasing its recently launched bioresorbable polymers technology platform and two new life sciences products during upcoming tradeshows, including CPHI Barcelona, October 24-26, in…
Conduit Pharmaceuticals Partners With ClinConnect on Cocrystal Development Program
Collaboration underscores Conduit’s mission to advance promising treatments by developing assets that have already completed Phase 1 trials….
Veranova Announces Appointment of New Advisory Board
Veranova recently announced the appointment of a new advisory board that will provide expert scientific and strategic guidance on the company’s journey to create the leading provider of….
Olema Oncology Announces Expansion of Collaboration Agreement With Novartis
Olema Pharmaceuticals, Inc. recently announced an amendment to its existing clinical collaboration and supply agreement with Novartis Institutes for BioMedical Research, Inc. to increase the size of….
BioXcel Therapeutics Reports Positive Overall Survival Results From Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients With Small Cell Neuroendocrine Prostate Cancer
BioXcel Therapeutics, Inc. recently announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the company's investigational oral innate immune activator, in…
AviadoBio Announces Initiation of Phase 1/2 Clinical Trial Evaluating AVB-101 in People With Frontotemporal Dementia With GRN Mutations
AviadoBio recently announced it has initiated the Phase 1/2 ASPIRE-FTD clinical study of its investigational gene therapy, AVB-101, in people with frontotemporal dementia (FTD) with…
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences, Inc. recently announced the first healthy adult participant has been dosed in its Phase 1/2 clinical trial of MBX 1416, the company’s long-acting…
Salubris Biotherapeutics Presents Positive 6-Month Data From Phase 1b Clinical Trial of JK07
Salubris Biotherapeutics, Inc. recently announced positive updated results from the completed Phase 1b study of JK07 in patients with HFrEF. The data were presented in…
Tenaya Therapeutics Presents Encouraging New Clinical & Preclinical Data From HDAC6 Inhibitor Program for the Potential Treatment of Heart Failure With Preserved Ejection Fraction
Tenaya Therapeutics, Inc. recently released new data for TN-301 at the 2023 Heart Failure Society of America (HFSA) Annual Scientific Meeting. TN-301 is Tenaya’s highly…
Sharp Acquires Berkshire Sterile Manufacturing
Sharp recently announced the acquisition of Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish contract development and manufacturing organization (CDMO) for….
Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical & Clinical Drug Development
Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and drug monitoring….
Ocular Therapeutix Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
Ocular Therapeutix, Inc. recently announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the company’s axitinib intravitreal implant, for the treatment of…
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Eton Pharmaceuticals recently announced it has entered into an agreement to acquire an abbreviated new drug application for Nitisinone Capsules via Oakrum Pharma, LLC’s Chapter…
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs & Expansion of IP Portfolio for Sublingual Film
BioXcel Therapeutics, Inc. recently provided an update on recent developments with its late-stage clinical programs as well as its patent portfolio for IGALMI (dexmedetomidine) sublingual…
Advent International & Warburg Pincus Complete Acquisition of Baxter’s BioPharma Solutions Business
Advent International, one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, recently announced the completion of their previously announced acquisition of Baxter International Inc.’s BioPharma Solutions (BPS) business….
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received US FDA Fast Track Designation for the Treatment of Extensive Stage Small Cell Lung Cancer & Extrapulmonary Neuroendocrine Cancers
Oxford BioTherapeutics (OBT) recently announced the US FDA has granted Fast Track designation to BI 764532 for the treatment of extensive stage small cell lung…
